Clinical evaluation of moxalactam.
Moxalactam was administered intravenously or intramuscularly or both in doses of 1 to 12 g/day to 45 patients with clinically significant infections (17 soft tissue or bone, 9 pleuropulmonary, 9 septicemic, 6 urinary tract, and 4 intraabdominal infections). Mean 0.5-h postinfusion levels were 105 mi...
Na minha lista:
| Publicado no: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology (ASM)
1982
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC182011/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6213198/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.21.5.780 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|